Coexpression of estrogen receptor and β

Poor prognostic factors in human breast cancer

Valerie Speirs, Alicia T. Parkes, Michael J. Kerin, David S. Walton, Peter J. Carleton, John N. Fox, Stephen Atkin

Research output: Contribution to journalArticle

217 Citations (Scopus)

Abstract

The cloning of a second estrogen receptor (ER), ERβ, has prompted a reevaluation of the role of ERs in breast cancer. The aim of this study was to determine the expression of both ER isoforms in normal (n = 23) and malignant (n = 60) human breast tissue by reverse transcription-PCR and correlate this information with known prognostic factors including tumor grade and node status. In normal breast tissue, expression of ERβ predominated, with 22% of samples exclusively expressing ERβ; this was not observed in any of the breast tumor samples investigated. Most breast tumors expressed ERα, either alone or in combination with ERβ. Interestingly, those tumors that coexpressed ERα and ERβ were node positive (P = 0.02; Fisher's exact test) and tended to be of higher grade. Because antiestrogens are agonists when signaling through the AP1 element, overexpression of ERβ in tumors expressing both ER subtypes may explain the failure of antiestrogen therapy in some breast cancer patients. Thus, ERβ may be a useful prognostic factor in patients with breast cancer.

Original languageEnglish
Pages (from-to)525-528
Number of pages4
JournalCancer Research
Volume59
Issue number3
Publication statusPublished - 1 Feb 1999
Externally publishedYes

Fingerprint

Estrogen Receptors
Breast Neoplasms
Estrogen Receptor Modulators
Breast
Neoplasms
Reverse Transcription
Organism Cloning
Protein Isoforms
Polymerase Chain Reaction

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Speirs, V., Parkes, A. T., Kerin, M. J., Walton, D. S., Carleton, P. J., Fox, J. N., & Atkin, S. (1999). Coexpression of estrogen receptor and β: Poor prognostic factors in human breast cancer. Cancer Research, 59(3), 525-528.

Coexpression of estrogen receptor and β : Poor prognostic factors in human breast cancer. / Speirs, Valerie; Parkes, Alicia T.; Kerin, Michael J.; Walton, David S.; Carleton, Peter J.; Fox, John N.; Atkin, Stephen.

In: Cancer Research, Vol. 59, No. 3, 01.02.1999, p. 525-528.

Research output: Contribution to journalArticle

Speirs, V, Parkes, AT, Kerin, MJ, Walton, DS, Carleton, PJ, Fox, JN & Atkin, S 1999, 'Coexpression of estrogen receptor and β: Poor prognostic factors in human breast cancer', Cancer Research, vol. 59, no. 3, pp. 525-528.
Speirs V, Parkes AT, Kerin MJ, Walton DS, Carleton PJ, Fox JN et al. Coexpression of estrogen receptor and β: Poor prognostic factors in human breast cancer. Cancer Research. 1999 Feb 1;59(3):525-528.
Speirs, Valerie ; Parkes, Alicia T. ; Kerin, Michael J. ; Walton, David S. ; Carleton, Peter J. ; Fox, John N. ; Atkin, Stephen. / Coexpression of estrogen receptor and β : Poor prognostic factors in human breast cancer. In: Cancer Research. 1999 ; Vol. 59, No. 3. pp. 525-528.
@article{70adb0b71a104fd4bba97fa4ba530fde,
title = "Coexpression of estrogen receptor and β: Poor prognostic factors in human breast cancer",
abstract = "The cloning of a second estrogen receptor (ER), ERβ, has prompted a reevaluation of the role of ERs in breast cancer. The aim of this study was to determine the expression of both ER isoforms in normal (n = 23) and malignant (n = 60) human breast tissue by reverse transcription-PCR and correlate this information with known prognostic factors including tumor grade and node status. In normal breast tissue, expression of ERβ predominated, with 22{\%} of samples exclusively expressing ERβ; this was not observed in any of the breast tumor samples investigated. Most breast tumors expressed ERα, either alone or in combination with ERβ. Interestingly, those tumors that coexpressed ERα and ERβ were node positive (P = 0.02; Fisher's exact test) and tended to be of higher grade. Because antiestrogens are agonists when signaling through the AP1 element, overexpression of ERβ in tumors expressing both ER subtypes may explain the failure of antiestrogen therapy in some breast cancer patients. Thus, ERβ may be a useful prognostic factor in patients with breast cancer.",
author = "Valerie Speirs and Parkes, {Alicia T.} and Kerin, {Michael J.} and Walton, {David S.} and Carleton, {Peter J.} and Fox, {John N.} and Stephen Atkin",
year = "1999",
month = "2",
day = "1",
language = "English",
volume = "59",
pages = "525--528",
journal = "Journal of Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "3",

}

TY - JOUR

T1 - Coexpression of estrogen receptor and β

T2 - Poor prognostic factors in human breast cancer

AU - Speirs, Valerie

AU - Parkes, Alicia T.

AU - Kerin, Michael J.

AU - Walton, David S.

AU - Carleton, Peter J.

AU - Fox, John N.

AU - Atkin, Stephen

PY - 1999/2/1

Y1 - 1999/2/1

N2 - The cloning of a second estrogen receptor (ER), ERβ, has prompted a reevaluation of the role of ERs in breast cancer. The aim of this study was to determine the expression of both ER isoforms in normal (n = 23) and malignant (n = 60) human breast tissue by reverse transcription-PCR and correlate this information with known prognostic factors including tumor grade and node status. In normal breast tissue, expression of ERβ predominated, with 22% of samples exclusively expressing ERβ; this was not observed in any of the breast tumor samples investigated. Most breast tumors expressed ERα, either alone or in combination with ERβ. Interestingly, those tumors that coexpressed ERα and ERβ were node positive (P = 0.02; Fisher's exact test) and tended to be of higher grade. Because antiestrogens are agonists when signaling through the AP1 element, overexpression of ERβ in tumors expressing both ER subtypes may explain the failure of antiestrogen therapy in some breast cancer patients. Thus, ERβ may be a useful prognostic factor in patients with breast cancer.

AB - The cloning of a second estrogen receptor (ER), ERβ, has prompted a reevaluation of the role of ERs in breast cancer. The aim of this study was to determine the expression of both ER isoforms in normal (n = 23) and malignant (n = 60) human breast tissue by reverse transcription-PCR and correlate this information with known prognostic factors including tumor grade and node status. In normal breast tissue, expression of ERβ predominated, with 22% of samples exclusively expressing ERβ; this was not observed in any of the breast tumor samples investigated. Most breast tumors expressed ERα, either alone or in combination with ERβ. Interestingly, those tumors that coexpressed ERα and ERβ were node positive (P = 0.02; Fisher's exact test) and tended to be of higher grade. Because antiestrogens are agonists when signaling through the AP1 element, overexpression of ERβ in tumors expressing both ER subtypes may explain the failure of antiestrogen therapy in some breast cancer patients. Thus, ERβ may be a useful prognostic factor in patients with breast cancer.

UR - http://www.scopus.com/inward/record.url?scp=0033083820&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033083820&partnerID=8YFLogxK

M3 - Article

VL - 59

SP - 525

EP - 528

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0008-5472

IS - 3

ER -